Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Fusion Antibodies confirms £0.28m tax credit

(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies announced the successful receipt of a research and development tax credit from HMRC on Thursday. The AIM-traded firm said the tax credit pertained to the financial year ended 31 March 2023, and was attributed to its efforts in advancing and refining the 'OptiMAL' platform, along with other endeavours in bioinformatics, antigen design, and cell culture.

It said the awarded tax credit met its expectations, amounting to almost £0.28m.

"The research and development tax credit system is of enormous benefit to companies developing cutting edge technologies such as we continue to do at Fusion," said chief executive officer Adrian Kinkaid.

"We are now beginning to reap the benefits of the resultant technology platforms with an elevated profile in our field and anticipate considerable commercial growth to be generated from them in the coming years."

At 1543 GMT, shares in Fusion Antibodies were up 1.05% at 4.8p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Ascential on track to hit targets this year
(Sharecast News) - Publishing, events and B2B consultancy group Ascential has said that trading is in line with expectations for the full year, helped by strong growth in marketing and fintech operations.
AstraZeneca's Imfinzi gets US approval for endometrial cancer patients
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
British Land CFO to join Kingfisher
(Sharecast News) - B&Q owner Kingfisher said it had appointed British Land chief financial officer Bhavesh Mistry to the same role at the home improvement company.
Ardian, Saudi fund to buy 37.6% stake in Heathrow
(Sharecast News) - Ferrovial - Heathrow's largest shareholder - said on Friday that it has agreed to sell a 37.6% stake in the London airport to the Saudi Public Investment Fund and French private equity firm Ardian for just under £3.3bn.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.